RT @AurelieRheumo: We would think that targeted therapies would have reduced GC use in RA. Well, this is not really the

We would think that targeted therapies would have reduced GC use in RA. Well, this is not really the case. Comaprison of GC use in 1999-2008 vs. 2009-2018 52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years! @RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm